RxDoctor Payments Data

Autumn Campbell, PA

Physician Assistant · Canton, OHNPI 1396110656

Payments from drug & device makers

$3,359in general payments, 2019–2025

Across 192 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$854
  • Bayer$384
  • Lilly USA, LLC$353
  • Insulet Corporation$148
  • Amgen$139
  • Dexcom, Inc.$131
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,33499%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,359 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$1,824
Medicare patients
19
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SomavertPegvisomant22$442,240
OzempicSemaglutide251$325,306
JardianceEmpagliflozin184$200,165
MounjaroTirzepatide120$123,757
TrulicityDulaglutide81$107,685
Tresiba Flextouch U-200Insulin Degludec84$96,209
Synjardy XrEmpagliflozin/Metformin Hcl51$65,028
FarxigaDapagliflozin Propanediol76$63,945
Tresiba Flextouch U-100Insulin Degludec68$52,264
Humalog Kwikpen U-200Insulin Lispro16$44,973
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$35,723
Humalog Kwikpen U-100Insulin Lispro90$34,887
Humulin R U-500 KwikpenInsulin Regular, Human18$34,787
TradjentaLinagliptin54$30,044
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog41$27,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerSomavert$20$442,24022 claims
Novo NordiskOzempic, Rybelsus$854$347,374267 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi$30$302,268301 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$353$235,600227 claims
AstraZenecaFarxiga$96$63,94576 claims
AbbVieSynthroid$25$10,365208 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$8,488956 claims
Sanofi-aventis U.S. LLCLantus$74$3,59918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →